VIA
IMNM icon

Virtus Investment Advisers’s Immunome IMNM Stock Holding History

Virtus Investment Advisers’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305K Buy
13,932
+339
+2% +$7.54K 0.08% 275
2025
Q4 		$292K Buy
13,593
+1,970
+17% +$34.6K 0.08% 259
2025
Q3 		$136K Buy
11,623
+2,018
+21% +$20.1K 0.04% 392
2025
Q2 		$89.3K Sell
9,605
-2,956
-24% -$24.2K 0.03% 382
2025
Q1 		$84.5K Buy
+12,561
New +$121K 0.02% 445

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Virtus Investment Advisers's IMNM Position: Q1 2026 in Review

Virtus Investment Advisers increased its Immunome (IMNM) stake by 2.5% in Q1 2026, buying an estimated $7.54K and bringing the position to 13,932 shares worth $305K. The position accounts for 0.08% of the portfolio, ranked #275.

Virtus Investment Advisers first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Virtus Investment Advisers held 13,932 shares of Immunome worth $305K as of Q1 2026.
  • Virtus Investment Advisers bought 339 Immunome shares in Q1 2026, an estimated $7.54K.
  • Immunome made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #275 holding.
  • Virtus Investment Advisers first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.